Martingale Asset Management L P acquired a new position in CureVac (NASDAQ:CVAC – Get Rating) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 41,042 shares of the company's stock, valued at approximately $805,000.

Other hedge funds have also recently bought and sold shares of the company. Capital Fund Management S.A. grew its position in CureVac by 131.9% in the 1st quarter. Capital Fund Management S.A. now owns 233,371 shares of the company's stock worth $4,576,000 after purchasing an additional 132,757 shares during the last quarter. California Public Employees Retirement System grew its holdings in CureVac by 0.6% in the 4th quarter. California Public Employees Retirement System now owns 120,622 shares of the company's stock worth $4,139,000 after buying an additional 735 shares in the last quarter. Bank of New York Mellon Corp increased its position in CureVac by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 103,549 shares of the company's stock valued at $2,030,000 after acquiring an additional 2,286 shares during the period. Eversept Partners LP acquired a new stake in CureVac in the 4th quarter valued at approximately $2,917,000. Finally, Bank of America Corp DE raised its stake in CureVac by 246.6% during the 4th quarter. Bank of America Corp DE now owns 72,885 shares of the company's stock valued at $2,501,000 after acquiring an additional 51,856 shares in the last quarter.

CureVac Price Performance

CureVac stock opened at $9.70 on Monday. CureVac has a 12-month low of $9.35 and a 12-month high of $71.63. The company has a current ratio of 3.45, a quick ratio of 3.39 and a debt-to-equity ratio of 0.06. The firm has a 50 day simple moving average of $13.14 and a 200-day simple moving average of $15.71.

Wall Street Analysts Forecast Growth

About CureVac

(Get Rating)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.

Read More

• Get a free copy of the StockNews.com research report on CureVac (CVAC)
• Could Snap Stock Rebound As Management Restructures?
• MarketBeat: Week in Review 8/29 – 9/2
• Hormel Looks Cheap At These Levels
• Lululemon Set To Soar Into September
• Could Nike Stock be Oversold, but Still Overvalued?

Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac (NASDAQ:CVAC – Get Rating).

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.